TSE:4528Pharmaceuticals
Ono Pharmaceutical (TSE:4528) Q3 EPS Surge Tests Bearish Margin Narratives
Ono Pharmaceutical (TSE:4528) opened Q3 2026 with revenue of ¥139,900 million, basic EPS of ¥61.42 and net income of ¥28,860 million, setting a clear marker for how its profitability is holding up. The company has seen quarterly revenue move from ¥134,223 million in Q3 2025 to ¥112,309 million in Q4 2025, then to ¥127,536 million in Q1 2026, ¥129,600 million in Q2 2026 and now ¥139,900 million in Q3 2026. Over the same period, basic EPS shifted from ¥31.83 to a loss of ¥13.93, then to ¥37.62,...